Gilead Sciences wants first dibs on all Assembly Biosciences’ programs. Rather than buy the viral disease biotech outright, Gilead is paying $100 million upfront for opt-in rights on all Assembly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback